NCT06465992View on ClinicalTrials.gov

Liposomal Bupivacaine With Dexamethasone for Foot Surgery

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Foot SurgeryAnkle SurgeryPost Operative PainPopliteal Nerve Block
Interventions
DRUG

Exparel 266 MG Per 20 ML Injection

20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block

DRUG

Bupivacaine Hcl 0.75% Inj

10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block

DRUG

Dexamethasone

1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block

Trial Locations (1)

19107

Rothman Orthopaedic Institute, Philadelphia

All Listed Sponsors
lead

Rothman Institute Orthopaedics

OTHER